Enhancement of Trans-Tympanic Drug Delivery by Pharmacological Induction of Inflammation

Zhang, Zipei; Li, Xiyu; Yang, Rong; Cullion, Kathleen; Prugneau, Laura; Kohane, Daniel S.

doi:10.1021/acs.molpharmaceut.2c00959

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diseases of the external ear requiring topical treatment are mainly associated with skin disorders. However, noninvasive trans-tympanic delivery of drugs to the middle ear has also gained interest, such as for instance for the administration of protective agents to treat druginduced ototoxicity (16) or of antibiotics for otitis media treatment (17,18). Topical antibiotics, corticosteroids, and anesthetics are commonly used for ototopical treatment and topical solutions (e.g., ear drops), suspensions, and ointments are typical dosage forms that are applied to the skin at the pinna, ear canal, and tympanic membrane.…”

Section: Introductionmentioning

confidence: 99%

Testing the In Vitro Product Performance of Mucosal Drug Products: View of the USP Expert Panel

Klein,

Sakagami,

et al. 2023

Dissolution Technol.

View full text Add to dashboard Cite

Performance testing of mucosal drug products presents the user with a multitude of challenges. Not only are there many different dosage forms to be distinguished, but also a wide variety of administration routes. The target action effect (local or systemic) is another factor to be considered. Thus, it quickly becomes apparent that there will never be a universal performance test, but the question arises just as quickly whether the method to be used should rather depend on the dosage form or the place of application, or even whether decisions must be made on an individual basis. This Stimuli article is one of a series of Stimuli articles on product performance testing, which focuses on methodological approaches and challenges in the field of performance testing of mucosal drug products. The article should be viewed as a supplement to, but also a critical discussion of the methods listed in USP general chapter Mucosal Drug Products-Performance Tests <1004>. With consideration of major physiologic aspects at the site of administration and the types of dosage forms to be studied, limitations of the methods described here and the need for methodologic updates or innovations are identified. Furthermore, suggestions are made for future activities, all aimed at developing robust, discriminatory, and meaningful test methods for the wide variety of mucosal drug products.

show abstract

Section: Introductionmentioning

confidence: 99%